SCHEMBL8201663

SCHEMBL8201663

FC(F)(F)c1ccccc1-c1cc(-c2ccc(C3=NCCN3)cc2)no1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
NISCH Q9Y2I1 5/20 0.48
MAOB P27338 8/20 0.47
MAOA P21397 7/20 0.47
HPGD P15428 2/20 0.45
ALDH1A1 P00352 1/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TOP2A P11388 2/20 0.43
TOP2B Q02880 2/20 0.43
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8214278 0.80 ALDH1A1 (0.65) CYP1A2NISCHMAOBMAOAHPGD
SCHEMBL29065449 0.80 NPC1 (0.60) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL1794747 0.80 TOP2A (0.61) CYP1A2NISCHMAOBMAOAHPGD
SCHEMBL8203245 0.80 NISCH (0.48) CYP1A2NISCHMAOBMAOAHPGD
Hydrochloric Acid SCHEMBL1795721 0.79 TOP2A (0.62) CYP1A2NISCHMAOBMAOAHPGD
SCHEMBL8201404 0.77 NISCH (0.56) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL1796041 0.77 NISCH (0.56) CYP1A2NISCHMAOBMAOAHPGD
Hydrochloric Acid SCHEMBL8196753 0.76 TOP2A (0.55) CYP1A2NISCHMAOBMAOAHPGD
Hydrochloric Acid SCHEMBL1796884 0.76 NISCH (0.55) CYP1A2NISCHMAOBMAOAHPGD
SCHEMBL8211455 0.74 NISCH (0.65) CYP1A2NISCHMAOBMAOAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000078726-A1 IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES ELI LILLY AND COMPANY (US) 2000-12-28 WO disclosed